Citius Pharmaceuticals, Inc. — Form 10-Q Summary
Reporting period: Three months ended December 31, 2021 (the company’s fiscal first quarter of 2022). Comparative results are for the three months ended December 31, 2020. Financial statements are unaudited.
Business context and financial performance
Citius is a development-stage specialty pharmaceutical company focused on critical-care products, including Mino-Lok, Mino-Wrap, Halo-Lido, I/ONTAK and a NoveCite cellular therapy for ARDS. It reported no revenue in either comparative quarter.
| Metric | Quarter ended Dec. 31, 2021 | Prior-year quarter |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $5.46 million | $6.19 million |
| General and administrative expense | $2.90 million | $1.69 million |
| Stock-based compensation | $0.90 million | $0.28 million |
| Total operating expenses | $9.26 million | $8.16 million |
| Operating loss | $9.26 million | $8.16 million |
| Net loss | $9.23 million | $8.15 million |
| Net loss per share, basic and diluted | $0.06 | $0.15 |
| Net cash used in operations | $4.65 million | $9.56 million |
Margins are not meaningful because the company had no revenue. At December 31, 2021, cash and cash equivalents were $65.42 million, working capital was approximately $60.6 million, and total assets were $137.52 million. Total liabilities were $12.96 million, including $4.99 million of deferred tax liability and $0.81 million of operating lease liabilities. The company reported no interest-bearing debt at quarter-end; related-party notes had been repaid in June 2021 and the PPP loan was forgiven in July 2021.
Changes versus the prior-year quarter
- Net loss increased by $1.08 million, primarily as G&A expense rose $1.21 million due mainly to additional employee compensation and performance bonuses.
- R&D expense declined $0.73 million. The prior-year quarter included a $5.0 million NoveCite license fee; in the current quarter, I/ONTAK R&D expense was $2.94 million. Halo-Lido costs increased by $0.77 million, while Mino-Lok costs increased by $0.26 million.
- Operating cash use improved by $4.91 million year over year. The filing attributes the current-quarter cash flow, in part, to changes in working capital; net loss was higher.
- Cash declined $4.65 million from September 30, 2021. Cash at December 31, 2020 was $4.30 million, versus $65.42 million at the current quarter-end, following substantial 2021 equity offerings and warrant exercises.
Outlook, risks and unusual items
- Management estimated existing cash resources would fund operations through March 2023 and said additional capital would be needed to support operations beyond then. There is no assurance financing will be available on acceptable terms or in time.
- The company expects R&D expense to increase in fiscal 2022 as it advances Phase 3 trials for Mino-Lok and I/ONTAK, progresses Halo-Lido, and continues work on ARDS and Mino-Wrap.
- Citius paid $40 million upfront to acquire the I/ONTAK license in 2021. The agreements also provide for substantial contingent development and commercial milestones, royalties, sublicense-payment obligations and, for I/ONTAK, reimbursement of certain clinical-trial and regulatory costs.
- Management cautioned that commercialization depends on clinical and regulatory outcomes, market acceptance, and access to additional capital or strategic partners. The company has no operating revenue to date and states that inability to secure funding or generate product revenue could materially adversely affect its business.
- The filing reported no legal proceedings, no material change in risk factors from the September 2021 Form 10-K, no off-balance-sheet arrangements, and no material change in internal control over financial reporting. Disclosure controls were assessed as effective.
Important facts for investors to verify
- Whether the stated cash runway through March 2023 remains adequate as clinical and development spending changes.
- Progress, costs, timelines and regulatory outcomes for the Mino-Lok and I/ONTAK programs, including the status of the I/ONTAK clinical trial and BLA preparation.
- Potential financing needs, the terms and timing of any future capital raising, and the effect of outstanding warrants and stock options on dilution.
- The amount and timing of contingent milestone, royalty and other payment obligations under the company’s product licenses.
- The filing says the quarter’s cash use reflected working-capital changes; investors may wish to review the cash-flow statement and accrued-liability movements alongside operating expenses.